MedTrace Logo

Tricaprilin Phase 2 Pilot Study in Migraine

NCT04437199 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2024-02-08

No results posted yet for this study

Summary

This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of tricaprilin as AC-SD-03 compared with placebo for the reduction of migraine in participants with frequent migraine.

Conditions

Interventions

DRUG

Tricaprilin

Powder formulation will be mixed with 240 mL water and shaken until fully dispersed. Each dosing unit of 12.5 g of AC-SD-03 contains 5 g of the active ingredients (tricaprilin)

DRUG

Placebo

Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.

Sponsors & Collaborators

  • Cerecin

    lead INDUSTRY

Principal Investigators

  • Study Director · Cerecin

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-17
Primary Completion
2022-02-07
Completion
2022-02-07

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04437199 on ClinicalTrials.gov